The scope of this report is limited to evaluating drug stability with respect to spaceflight. The effects of spaceflight on drug pharmacokinetics (PK) or drug pharmacodynamics (PD) are not addressed in this report: these topics will be reviewed in future reports. This is the first report of the available evidence pertaining to the chemical and physical stability of drugs in the context of drug impurity, drug repackaging, and exposure to ionizing space radiation. Previous studies are discussed within this report and, where possible, the data are interpreted and contextualized with regards to drug stability.
Evidence Report: Risk of Ineffective or Toxic Medication During Long-Duration Exploration Spaceflight
2023-12-20
Miscellaneous
No indication
English
Plasma Cytokine Levels During Long-Duration Spaceflight
NTRS | 2011
|Personal growth following long-duration spaceflight
Online Contents | 2012
|